<DOC>
	<DOCNO>NCT01569516</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy Octohydroaminoacridine Succinate tablet find optimal dose patient mild moderate Alzheimer 's Disease .</brief_summary>
	<brief_title>Study Octohydroaminoacridine Succinate Tablets Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>The purpose study preliminary assessment Octohydroaminoacridine Succinate tablet treatment mild moderate Alzheimer 's disease explore efficacy safety best dose . The 288 patient randomly assign four group : high dose ( 4mg / time ) , moderate dose ( 2mg / time ) , low dose ( 1mg / time ) placebo group , include four week trial screen period follow 16 week double-blind treatment .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Clinical diagnosis probable AD base DSMIV NINCDSADRDA criterion . 2 . Male/female patient age 50 85 . 3. mild moderate probable AD ：Middle school : 11 ≤MMSE ≤ 25 , elementary school : 8 ≤ MMSE ≤ 20 , illiteracy : 5 ≤ MMSE ≤ 16 . 4 . CT MRI scan exclude another structural brain disease one year . 5 . Neurologic examination significant abnormality . 6 . Hachinski Ischemic Score &lt; 4；Hamilton Depression Scale ≤10 . Able complete test procedure , audiovisual physical ability act complete neuropsychological measure . 7 . Stable chaperone , 2 hour day together patient accumulate few 14 hour per week . 8 . Informed consent patient ( legal representative ) caregiver agree take part study . 1 . Proven clinically suspect type dementia vascular dementia , Lewy body dementia , Parkinson 's disease , frontotemporal dementia , g Jakob disease ( spastic pseudosclerosis ) , normal pressure hydrocephalus etc . 2 . Sudden onset early dementia gait disorder , seizures behavioral change . 3 . Clinical manifestation focal neurological sign ( hemiparesis , sensory loss , visual field defect ) early extrapyramidal tract sign . 4 . History cerebrovascular disease stroke . 5 . Serious lack folic acid VitB12 , syphilis antibody positive thyroid dysfunction . 6 . Mechanical intestinal obstruction patient , Resting pulse less 60 , Severe liver renal disease . 7 . Patients mechanical intestinal obstruction . 8 . History bone marrow transplantation.Mental illness , severe depression . 9 . Cognitive damage cause alcohol drug abuse . Disable correctly evaluate cognitive function . 10 . Critical condition , disable make exact evaluation efficacy safety new drug . 11 . Use agent treatment dementia within 4 week randomization . 12 . Be sensitive ACHEI . 13 . Be sensitive two foods/drugs . 14 . Use another investigational agent within one month screen .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Octohydroaminoacridine Succinate</keyword>
</DOC>